Chromosome 14q loss is associated with adverse survival and a distinct transcriptional phenotype in IDH-wildtype glioblastoma
Journal of Neuro-Oncology · 2026-11 · 180 (2)
DOI: 10.1007/s11060-026-05855-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 10.11.2026. Verfasst von Nayuta Higa und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8…. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Isocitrate Dehydrogenase, Biomarkers, Tumor. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kagoshima University.
Abstract (Originalsprache)
Purpose
In IDH-wildtype glioblastoma, prognostic biomarkers beyond MGMT promoter methylation remain limited. Chromosome 14q contains candidate tumor suppressors, yet the significance of arm-level 14q loss in molecularly defined glioblastoma is unclear.
Methods
Arm-level 14q status was inferred from coordinated 14q expression (Gaussian-mixture model) in bulk RNA sequencing of 215 Japanese IDH-wildtype glioblastomas and validated against methylation-array copy number ( n = 42). Associations with outcome and transcriptional programs were evaluated and assessed in CGGA ( n = 74) and TCGA ( n = 139) using the discovery-cohort threshold.
Results
RNA-seq-based calls agreed with array copy number in 40/42 cases (κ = 0.90). 14q loss (87/215, 40.5%) was associated with shorter overall ( p = 0.0053) and progression-free survival ( p = 0.0175), remaining prognostic in the prespecified multivariable model (hazard ratio 1.44, 95% confidence interval 1.02–2.01; p = 0.036). 14q loss and MGMT promoter hypomethylation were prognostically complementary (four-group p < 0.0001). Chromosome 14-excluded, purity-adjusted gene set enrichment analysis showed increased E2F-target and G2M-checkpoint and reduced oxidative-phosphorylation and lipid-metabolism programs in 14q-loss tumors. The survival association was reproduced in CGGA ( p = 0.0012) but not in TCGA ( p = 0.55), with significant heterogeneity (interaction p = 0.005).
Conclusion
RNA-seq-inferable 14q loss identifies a clinically adverse subgroup of Japanese IDH-wildtype glioblastoma, is complementary to MGMT promoter methylation, and is associated with a proliferation-high, oxidative-phosphorylation-low transcriptional state. The absence of this association in TCGA underscores the need for validation in additional population-diverse cohorts before clinical implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan. nayuhiga@m.kufm.kagoshima-u.ac.jp.
- Department of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8544, Japan.
- Center for Human Genome and Gene Analysis, Kagoshima University Hospital, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8544, Japan.
- Department of Neurosurgery, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan.
- Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
- Department of Neurosurgery, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, 807-8555, Japan.
ORCID-Profile: Nayuta Higa
Förderung
- Kagoshima University
Zitieren
APA
Higa, N., Yokoyama, S., Akahane, T., Hamada, T., Yonezawa, H., Makino, R., Takajo, T., Matsuo, K., Kirishima, M., Kitazono, I., Fujioka, Y., Hatae, R., Kuga, D., Nagasaka, S., Suzuki, K., Yamamoto, J., Yoshimoto, K., Tanimoto, A., & Hanaya, R. (2026). Chromosome 14q loss is associated with adverse survival and a distinct transcriptional phenotype in IDH-wildtype glioblastoma. Journal of Neuro-Oncology, 180(2). https://doi.org/10.1007/s11060-026-05855-2
Vancouver
Higa N, Yokoyama S, Akahane T, Hamada T, Yonezawa H, Makino R, et al. Chromosome 14q loss is associated with adverse survival and a distinct transcriptional phenotype in IDH-wildtype glioblastoma. Journal of Neuro-Oncology. 2026;180(2). doi:10.1007/s11060-026-05855-2
BibTeX
@article{Higa2026,
author = {Higa, Nayuta and Yokoyama, Seiya and Akahane, Toshiaki and Hamada, Taiji and Yonezawa, Hajime and Makino, Ryutaro and Takajo, Tomoko and Matsuo, Kei and Kirishima, Mari and Kitazono, Ikumi and Fujioka, Yutaka and Hatae, Ryusuke and Kuga, Daisuke and Nagasaka, Shohei and Suzuki, Kohei and Yamamoto, Junkoh and Yoshimoto, Koji and Tanimoto, Akihide and Hanaya, Ryosuke},
title = {Chromosome 14q loss is associated with adverse survival and a distinct transcriptional phenotype in IDH-wildtype glioblastoma},
journal = {Journal of Neuro-Oncology},
year = {2026},
volume = {180},
number = {2},
doi = {10.1007/s11060-026-05855-2}
}
EUVIMED